There are currently 66 clinical trials in Arlington, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Texas Clinical Research Institute, GSK Investigational Site, Texas Clinical Research Institute, Llc and Texas Retina Associates. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects
NCT04505436
Recruiting
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/13/2024
Locations: Texas Clinical Research Institute, LLC, Arlington, Texas
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: The Center for Cancer and Blood Disorders - Magnolia,515 W. Mayfield Rd., Arlington, Texas
Conditions: Triple Negative Breast Cancer, PD-L1 Positive
Register for Updates
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376
Recruiting
The primary objective of this study to evaluate the efficacy of ravulizumab compared with placebo to reduce proteinuria and slow the rate of eGFR decline in adult participants with IgAN who are at risk of disease progression.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Research Site, Arlington, Texas
Conditions: Immunoglobulin A Nephropathy, IgAN
Register for Updates
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237
Recruiting
The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on progression-free survival (PFS) and overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Arlington Cancer Center, Arlington, Texas
Conditions: Non-small Cell Lung Cancer
Register for Updates
ABTECT - Maintenance
NCT05535946
Recruiting
This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins,... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
04/23/2024
Locations: Texas Clinical Research Institute, LLC, Arlington, Texas
Conditions: Ulcerative Colitis
Register for Updates
Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts
NCT05799157
Recruiting
This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris
Gender:
All
Ages:
Between 12 years and 65 years
Trial Updated:
04/23/2024
Locations: Site 03, Arlington, Texas
Conditions: Verruca Vulgaris, Warts, Common Wart
Register for Updates
Effects of Exercise and Virtual Reality on Depression
NCT05973461
Recruiting
This study is evaluating the effects of riding on a cycle ergometer while experiencing virtual reality to determine its effect on mood.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/08/2024
Locations: UTArlington, Arlington, Texas
Conditions: Symptoms of Depression
Register for Updates
A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)
NCT05685433
Recruiting
A prospective, multicenter, single-arm study to evaluate the safety and effectiveness of the eCoin® implanted tibial nerve stimulator in subjects with urgency urinary incontinence (UUI).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/06/2024
Locations: UPNT Research Institute, Arlington, Texas
Conditions: Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
Register for Updates
Black Women's Life Experience On Cardiovascular Health Via Ongoing Monitoring
NCT06150989
Recruiting
This pilot study uses a state-of-the-science combination of remote behavioral monitoring, real-time experience sampling, in-lab physiological assessments, and extraction of neighborhood-level characteristics to (1) Examine the impact of daily experience (i.e., racial discrimination, affective states, stress) on health behaviors (i.e., physical activity, sedentary behavior, sleep) at the intrapersonal level among Black women; (2) Test the association between daily behaviors and impairments in bio... Read More
Gender:
Female
Ages:
Between 18 years and 49 years
Trial Updated:
04/03/2024
Locations: The University of Texas at Arlington, Arlington, Texas
Conditions: Cardiovascular Diseases, Heart Disease Risk Factors
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)
NCT04123795
Recruiting
The purpose of the study is to demonstrate the efficacy and safety of certolizumab pegol in the treatment of moderate to severe chronic plaque psoriasis in study participants aged 6 to 11 and 12 to 17 years.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
03/28/2024
Locations: Ps0007 50156, Arlington, Texas
Conditions: Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis
Register for Updates
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
NCT04757610
Recruiting
A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
Gender:
All
Ages:
50 years and above
Trial Updated:
03/26/2024
Locations: ShORe Investigational Site, Arlington, Texas
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222
Recruiting
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Texas Clinical Research Institute, Arlington, Texas
Conditions: NASH, Cirrhosis, Liver
Register for Updates